Immuno-Biological Laboratories Co., Ltd.

2026/08/21 Updated
Market Cap: $62.6M (¥9.9B)
Stock Price: $6.72 (¥1,068)
Exchange Rate: 1 USD = ¥158.98

Stock Price Chart

2026/08/21 Updated
30.20
PER (Price Earnings Ratio)
vs Industry Avg: +20.7
5.27
PBR (Price to Book Ratio)
vs Industry Avg: +4.0
0.68%
Dividend Yield
vs Industry Avg: -2.27%

Price Trend

2026/08/21 Updated
Short-term
5-Day MA
+1.44%
Near-term
25-Day MA
+8.52%
Mid-term
75-Day MA
+3.45%
Long-term
200-Day MA
-18.56%

Price & Trading Details

2026/08/21 Updated

PRICE

Previous Close ¥1,098
Open ¥1,084
High ¥1,084
Low ¥1,048
Close ¥1,068

TRADING

Volume 119,100
Average Volume 116,228
Turnover ¥1億
Min. Purchase ¥106,800

Shareholder Composition

Updated 2026/08/01
19.0%
Insider Holdings
1.1%
Institutional
80.0%
Public Float
1
Institutional Holders
Insider Holdings 19.0%
Institutional 1.1%
Public Float 80.0%

Dividend History 1Years Growth

Updated 2026/08/23
-%
Dividend Yield
¥6
Annual Dividend
+20.0%
YoY Growth
17.0%
Payout Ratio
Year Dividend Change
2026 ¥6 +20.0%
2013 ¥5 -

Financial Performance

2026/08/23 Updated

Revenue & Profit

Margins

Cash Flow

Financial Health

2023 2024 2025 2026
Income Statement
Revenue ¥795M ¥817M ¥970M ¥1,005M
Gross Profit ¥527M ¥517M ¥634M ¥707M
Operating Income ¥57M ¥104M ¥209M ¥281M
Pretax Income -¥280M ¥126M ¥211M ¥302M
Net Income -¥290M ¥187M ¥249M ¥329M
EPS -¥31.10 ¥20.05 ¥26.74 ¥35.33
Operating Margin 7.19% 12.77% 21.59% 27.99%
Balance Sheet
Total Assets ¥1,434M ¥1,619M ¥1,845M ¥2,155M
Total Equity ¥1,079M ¥1,265M ¥1,514M ¥1,843M
Total Liabilities ¥356M ¥353M ¥331M ¥312M
Cash ¥614M ¥734M ¥826M ¥989M
Interest-bearing Debt ¥235M ¥236M ¥204M ¥177M
Equity Ratio 75.20% 78.17% 82.06% 85.53%
D/E Ratio 0.22 0.19 0.13 0.10
Cash Flow
Operating CF ¥26M ¥134M ¥183M ¥301M
Investing CF ¥30M -¥24M -¥54M -¥116M
Financing CF ¥1M ¥1M -¥32M -¥27M
Free CF ¥26M ¥115M ¥124M ¥268M
Efficiency
ROE -26.86% 14.75% 16.45% 17.85%
ROA -20.20% 11.53% 13.50% 15.27%

Latest IR Information

Company Information

English Name Immuno-Biological Laboratories Co., Ltd.
Japanese Name (株)免疫生物研究所
Stock Code 4570.T (JPX)
Sector / Industry Healthcare / Biotechnology
Employees 54

About

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer's disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtration high performance liquid chromatography method that can profile various clinical samples, such as tiny plasma or serum samples from both small animals and human beings for broad range of research fields including lipid metabolism, development of drugs for life-style related diseases, development of functional supplemental foods, and clinical studies. In addition, the company offers LipoTEST, a support tool for diagnostic and health checks at animal clinics; and customized biomarker testing services for Life-style related diseases. Further, it operates protein production business using transgenic silkworms for manufacturing of antibodies for research reagents and diagnostic products; human collagen for cosmetic materials; development of proteins for use in drugs; and other proteins production. The company was incorporated in 1982 and is headquartered in Fujioka, Japan.

Data provided by Yahoo Finance